Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Multi-omics-guided diagnosis and treatment of toxoplasma retinochoroiditis with co-infection: a case report.

Created on 12 Jul 2026

Authors

Qiongjun Xie, Jingyue Deng, Caiyin Mo, Xiaoshan Lin, Qian Shi, Anyi Liang, Guanghua Zhou

Published in

BMC ophthalmology. Jul 11, 2026. Epub Jul 11, 2026.

Abstract

Toxoplasma retinochoroiditis is challenging to diagnose and treat, especially in immunocompromised or co-infected individuals. This report describes a complex vision loss case in a syphilis and tuberculosis-history patient, demonstrating the utility of multi-omics in guiding diagnosis and treatment. A 50-year-old female with treated syphilis and tuberculosis had right eye floaters and visual disturbances, with panuveitis and retinal lesions on exam. Aqueous humor multi-omics confirmed Toxoplasma gondii (no syphilis or tuberculosis DNA), and she recovered with 8-week trimethoprim-sulfamethoxazole plus tapered prednisone (initiated 72h post-antimicrobial therapy).
This case highlights the diagnostic challenges of ocular inflammation in patients with co-infections and demonstrates the value of multi-omics-guided intraocular fluid analysis for precise pathogen identification. This case supports a combined treatment strategy of anti-toxoplasmosis medication and cautious corticosteroid use, which-despite the risk of reactivating latent infections-can achieve excellent anatomical and visual outcomes.

PMID:
42436394
Bibliographic data and abstract were imported from PubMed on 12 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 9
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement